The Week in Review: April 6 – April 13, 2018

Friday, April 13, 2018 News Recap: Canada: Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...

Initiative aims to treat Hepatitis C in Alberta patients who also have HIV

NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to patients at an advanced stage of the disease or those with complications. A long-term effort to eliminate hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. Dr. Stephen Shafran, an infectious disease expe

The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

Nova Scotia: New drug will help with hepatitis C treatment

Nova Scotians will soon have access to a new drug to help treat hepatitis C. Nova Scotia’s Department of Health and Wellness announced Monday the province will provide public access to EPCLUSA tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C. With this drug, patients take one tablet daily for 12 weeks, provided they are adult patients without cirrhosis or with compensat

Ontario Becomes First Province To List EPCLUSA™ On Public Drug Plan To Treat All Six Genotypes Of Chronic Hepatitis C Infection

Ontario Also Broadens Access for Patients with Less Advanced Disease with Co-Factors —MISSISSAUGA, ON, Feb. 22, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective February 28th, 2017, Ontario will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.  This listing